These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9823572)

  • 1. [Interferon treatment of chronic hepatitis C viral hepatitis patients with normal transaminases].
    Remy AJ; Blanc P
    Gastroenterol Clin Biol; 1998; 22(8-9):748-9. PubMed ID: 9823572
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of patients with chronic hepatitis C virus infection and normal transaminases].
    Serfaty L
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B202-5. PubMed ID: 12180289
    [No Abstract]   [Full Text] [Related]  

  • 3. [Predicting factors in the efficacy of interferon treatment in chronic hepatitis C].
    Rodríguez Agulló JL
    An Med Interna; 2001 Jul; 18(7):349-50. PubMed ID: 11534417
    [No Abstract]   [Full Text] [Related]  

  • 4. [The effect of iron depletion on the response to interferon treatment in patients with chronic hepatitis C. Pilot study].
    Ortiz V; Olaso V; López Viedma B; Córdoba J; Molina JM; Lainez B; Pastor M; Berenguer J
    Gastroenterol Hepatol; 1999 Mar; 22(3):122-6. PubMed ID: 10228321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chronic hepatitis C. Treatment of special groups].
    Civeira MP
    Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():68-70. PubMed ID: 11968348
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of patients with hepatitis C and normal serum aminotransferase levels.
    Bacon BR
    Hepatology; 2002 Nov; 36(5 Suppl 1):S179-84. PubMed ID: 12407592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of chronic hepatitis C and alcohol consumption].
    Mathurin P; Canva V; Dharancy S; Paris JC
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B248-51. PubMed ID: 12180297
    [No Abstract]   [Full Text] [Related]  

  • 8. [Interferon therapy in chronic hepatitis C and cellular immunity].
    Nikitin IG; Kuznetsov SL; Mordvinova LN; Uskov IuI; Storozhakov GI; Strochenovskiĭ AB
    Klin Med (Mosk); 1999; 77(6):33-7. PubMed ID: 10459217
    [No Abstract]   [Full Text] [Related]  

  • 9. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
    Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K
    J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of chronic hepatitis C in patients without previous treatment].
    Dehesa Violante M
    Rev Gastroenterol Mex; 2002 Oct; 67 Suppl 2():S42-4. PubMed ID: 12712852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of chronic hepatitis C in patients not responding to interferon].
    Moreno Monteagudo JA; García Buey L; Moreno Otero R
    Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():51-6. PubMed ID: 11968345
    [No Abstract]   [Full Text] [Related]  

  • 12. Liver function under interferon/ribavirin therapy of chronic hepatitis C.
    Stintzing S; Schmitt C; Ocker M; Ganslmayer M; Zopf S; Gahr S; Hahn EG; Herold C
    Hepatogastroenterology; 2009; 56(90):462-5. PubMed ID: 19579621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors that predict the response to interferon in patients with chronic hepatitis C: clinical management of individual patients.
    Lo Iacono O
    Rev Esp Enferm Dig; 2000 Aug; 92(8):485-94. PubMed ID: 11084816
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of interferon therapy for aged patients with chronic hepatitis C.
    Arase Y; Kumada H
    J Gastroenterol; 2004 Nov; 39(11):1123-4. PubMed ID: 15580412
    [No Abstract]   [Full Text] [Related]  

  • 15. Interferon-based therapy for dialysis patients with chronic hepatitis C: progress and challenges.
    Liu CH; Liu CJ; Kao JH
    Nephrology (Carlton); 2007 Feb; 12(1):8-10. PubMed ID: 17295654
    [No Abstract]   [Full Text] [Related]  

  • 16. [Efficacy forecast on interferon in the treatment of chronic viral hepatitis].
    Mei YY; Gao ZL
    Zhonghua Gan Zang Bing Za Zhi; 2011 Jan; 19(1):8-9. PubMed ID: 21272450
    [No Abstract]   [Full Text] [Related]  

  • 17. Combined effect of an ACE inhibitor, perindopril, and interferon on liver fibrosis markers in patients with chronic hepatitis C.
    Yoshiji H; Noguchi R; Fukui H
    J Gastroenterol; 2005 Feb; 40(2):215-6. PubMed ID: 15770410
    [No Abstract]   [Full Text] [Related]  

  • 18. [Interferon treatment of chronic viral hepatitis in Catalonia, Spain. Retrospective analysis].
    Buti M; Bruguera M; Casany S; Gaspar MJ; Esteban R
    Gastroenterol Hepatol; 1999 Mar; 22(3):127-31. PubMed ID: 10228322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C.
    Romero-Gómez M; González-Escribano MF; Torres B; Barroso N; Montes-Cano MA; Sánchez-Muñoz D; Núñez-Roldan A; Aguilar-Reina J
    Am J Gastroenterol; 2003 Jul; 98(7):1621-6. PubMed ID: 12873589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon: the quintessence of a quinquagenarian.
    De Clercq E
    Verh K Acad Geneeskd Belg; 2009; 71(1-2):5-14. PubMed ID: 19739395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.